A client is about to be started on levodopa-carbidopa for treatment of Parkinson's disease. The nurse notices the client is currently taking a nonselective monoamine oxidase (MAO) inhibitor. Which severe complication may occur if these drugs are taken together?

Introduction: Parkinson's disease involves dopaminergic depletion in the substantia nigra. Combining levodopa, a dopamine precursor, with nonselective MAO inhibitors is contraindicated because it prevents the breakdown of catecholamines, leading to a massive, life-threatening accumulation of norepinephrine and dopamine within the systemic circulation. A. Concurrent administration of levodopa and nonselective MAOIs leads to excessive accumulation of catecholamines. This synergy triggers a HYPERTENSIVE CRISIS, characterized by a rapid, severe increase in blood pressure, tachycardia, and potential cerebrovascular accidents. Nonselective MAOIs must be discontinued at least 14 days prior to commencing any levodopa-based therapy. B. Gastrointestinal bleeding is not a primary complication associated with the interaction between levodopa-carbidopa and MAO inhibitors. While levodopa can cause nausea or vomiting, the specific synergistic risk of combining these two classes of medications is cardiovascular in nature, specifically involving the sympathetic nervous system's response to catecholamine overload. C. Fulminant liver failure is an acute loss of hepatic function not typically associated with the combination of levodopa and MAOIs. While some COMT inhibitors used in Parkinson's (like tolcapone) require liver monitoring, the immediate and most dangerous risk of the levodopa-MAOI interaction is the induction of a hypertensive emergency. D. Respiratory depression is generally associated with central nervous system depressants such as opioids or benzodiazepines. The interaction between levodopa and MAO inhibitors is stimulatory rather than inhibitory. It results in a hyper-sympathetic state, which would more likely cause tachypnea and agitation rather than a decrease in respiratory drive.